Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.…
Relay Therapeutics (RLAY) Could Be 26% Undervalued After Third Quarter 2026 Results
Relay Therapeutics (NASDAQ: RLAY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 218 employees.
The shares were at 16.12 USD on 20 November 2026, up 146.9% over 52 weeks. Its 52-week range is 5.950 USD to 21.27 USD: the price is 24.2% below the high and 170.9% above the low.
Its market capitalisation is 3.56B USD.
Relay Therapeutics reports return on equity of -48.8%.
It holds more cash than debt, a net cash position of 821.61M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 28.25 USD is 75.2% above the current price. The next earnings report is expected on 25 February 2027.